CB Insights
Technology Market Intelligence
Technology Market Intelligence
Rodin Therapeutics discovers and develops therapeutics by applying chemical strategies to target protein complexes that selectively modulate gene expression. On November 18, 2019, Rodin Therapeutics was acquired by Alkermes at a valuation of $100M.
Company (Acquired)
Phone:
101 Huntington Avenue
21st Floor, Suite 2150
Boston, 02199
Massachusetts, United States
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Investor | Investor Type | Location | Participating Rounds |
|---|---|---|---|
| Google Ventures | Corporate Venture | Mountain View, California, United States | Series B - II |
| Atlas Venture | Venture Capital | Cambridge, Massachusetts, United States | Series B - II, Series B, Series A, Seed VC |
| Biogen Idec New Ventures | Corporate Venture | Cambridge, Massachusetts, United States | Series B |
| Hatteras Venture Partners | Venture Capital | Durham, North Carolina, United States | Series B - II |
| Johnson & Johnson Innovation | Corporate Venture | New Brunswick, New Jersey, United States | Series A, Seed VC |
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Bicyclic inhibitors of histone deacetylase | Jan 11, 2018 | Oct 06, 2020 | Patent |
| Bicyclic inhibitors of histone deacetylase | Nov 12, 2019 | Jun 30, 2020 | Patent |
| Bicyclic inhibitors of histone deacetylase | Mar 23, 2018 | Dec 31, 2019 | Patent |
| Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase | Jul 05, 2016 | Sep 24, 2019 | Patent |
| Inhibitors of histone deacetylase | Jun 25, 2015 | May 29, 2018 | Patent |
